A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for United Therapeutics's Debt-to-Equity or its related term are showing as below:
UTHR'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.22 Max: 1.54
Current: 0.19
During the past 13 years, the highest Debt-to-Equity Ratio of United Therapeutics was 1.54. The lowest was 0.00. And the median was 0.22.
UTHR's Debt-to-Equity is ranked worse than 60.56% of 1103
companies
in the Biotechnology industry
Industry Median: 0.12
vs UTHR: 0.19
United Therapeutics Debt-to-Equity Historical Data
The historical data trend for United Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
United Therapeutics Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Debt-to-Equity
0.12
0.09
0.31
0.24
0.20
United Therapeutics Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Debt-to-Equity
0.22
0.21
0.20
0.19
0.19
Competitive Comparison
For the Biotechnology subindustry, United Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, United Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where United Therapeutics's Debt-to-Equity falls into.
United Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
United Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (NAS:UTHR) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
United Therapeutics Debt-to-Equity Related Terms
Thank you for viewing the detailed overview of United Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.17(0.98%) Volume: 10,886 9:50AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:UTHR has been successfully added to your 
